CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 351 enrolled
Drug / intervention
CM-1600device
Likely dose
CM-1600 device application during blood donationAI-extracted
Key inclusion· 4
  • Age 18 years or older
  • Able to provide written informed consent
  • Willing and able to comply with study procedures
  • Eligible to undergo a single unit whole blood donation
Key exclusion· 5
  • Pregnant or breastfeeding females
  • History of upper extremity amputation
  • Diagnosed with dextrocardia
  • Has a pacemaker

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05463198
NCT05463198N/ACompleted

Evaluation of Physiological Variables and Detection of Blood Loss Using the Zynex Fluid Monitoring System, Model CM-1600

Zynex Monitoring Solutions·interventional·Posted Jul 18, 2022·Updated Aug 13, 2024

In Brief

A clinical study evaluating CM-1600 for Fluid Loss. Completed, enrolled 351 participants across 4 sites.

Detailed Summary

The study is a prospective, non-randomized, non-blinded, non-significant risk, multi-center study enrolling up to 500 healthy adult subjects consented to undergo a whole blood donation procedure. The study will involve enrolling subjects that will undergo blood donation wearing the study device (CM-1600 Device) and capture study-required physiological parameters pre-, during, and post-donation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFluid Loss
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2023202420252026
First PostedJul 18, 2022
Enrollment StartSep 14, 2022
Primary CompletionApr 27, 2023
Study CompletionMay 26, 2023
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 4.0 years ago

Interventions

CM-1600device

Subjects undergoing blood donation will be connected to the CM-1600 device.